Dominika Kovács Selected Research

Interleukin-6 (Interleukin 6)

1/2021

Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dominika Kovács Research Topics

Disease

2	Inflammation (Inflammations) 12/2021 - 01/2021
1	Colitis 01/2021
1	Crohn Disease (Crohn's Disease) 01/2021
1	Neoplasms (Cancer) 01/2021

Drug/Important Bio-Agent (IBA)

1	TetralonesIBA 12/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	Poly (ADP-Ribose) Polymerase-1IBA 01/2021
1	olaparibIBA 01/2021
1	Sulfonic AcidsIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2021
1	sym-trinitrobenzeneIBA 01/2021

Therapy/Procedure

1	Therapeutics 01/2021